Interpretation of Vaginal Microbiome Test Results
Your test results indicate bacterial vaginosis (BV) with high levels of three key BV-associated bacteria: Atopobium vaginae, BVAB-2, and Megasphaera-1, all scoring "High-2" (abnormal). This molecular pattern is diagnostic of BV and represents disruption of the normal lactobacillus-dominant vaginal microbiome with overgrowth of anaerobic bacteria 1, 2.
What These Results Mean
Diagnostic Interpretation:
Atopobium vaginae (High-2): This bacterium shows 96% sensitivity and 93% specificity for BV diagnosis and is one of the most accurate single markers for the condition 3, 4.
BVAB-2 (High-2): BV-Associated Bacterium 2 (now identified as Oscillospiraceae bacterium strain CHIC02) is highly preponderant in BV and represents significant vaginal dysbiosis 5, 2.
Megasphaera-1 (High-2): This anaerobic bacterium is a validated positive indicator for BV and part of the polymicrobial proliferation characteristic of this condition 2, 3.
The combination of these three organisms at high levels (the "GAMB" panel: Gardnerella + Atopobium + Megasphaera + BVAB) demonstrates 87% sensitivity and 82% specificity for BV, with strong association with higher BV scoring 3.
Clinical Significance
BV is characterized by replacement of normal hydrogen peroxide-producing Lactobacillus species with high concentrations of anaerobic bacteria 6. Your results show this exact pattern.
Symptoms and Presentation:
- Approximately 50% of women meeting clinical criteria for BV have no symptoms 6.
- When symptomatic, BV typically presents with homogeneous white vaginal discharge, fishy odor, vaginal pH >4.5, and clue cells on microscopy 6, 7.
Associated Risks:
BV has been associated with serious complications including 6, 7:
- Pelvic inflammatory disease (PID)
- Endometritis and vaginal cuff cellulitis following invasive procedures (endometrial biopsy, hysterectomy, IUD placement, cesarean section, uterine curettage)
- Post-abortion PID (metronidazole treatment substantially reduced this risk in randomized controlled trials)
- In pregnancy: premature rupture of membranes, preterm labor, preterm birth, and postpartum endometritis 7
Treatment Recommendations
If you have symptoms (vaginal discharge, odor, irritation), treatment is indicated 6, 7. The principal goal of therapy is to relieve vaginal symptoms and signs of infection.
Recommended Treatment Regimens:
First-line options 7:
- Metronidazole 500 mg orally twice daily for 7 days (95% cure rate)
- Metronidazole gel 0.75%, one full applicator (5g) intravaginally once daily for 5 days
- Clindamycin cream 2%, one full applicator (5g) intravaginally at bedtime for 7 days
Alternative regimens 7:
- Metronidazole 2g orally single dose (84% cure rate, lower efficacy)
- Clindamycin 300mg orally twice daily for 7 days
- Clindamycin ovules 100g intravaginally once at bedtime for 3 days
Important precautions:
- Avoid alcohol during metronidazole treatment and for 24 hours after completion 6, 7
- Clindamycin cream is oil-based and may weaken latex condoms and diaphragms 7
Special Considerations:
Asymptomatic BV treatment should be considered before 7:
- Surgical abortion procedures (randomized controlled trial showed substantial reduction in post-abortion PID)
- Hysterectomy (trials showed 10-75% reduction in post-operative infectious complications)
- In high-risk pregnant women with history of preterm delivery 7, 8
Partner treatment is NOT recommended, as treatment of male sex partners has not been shown to alter clinical course or prevent recurrence 6, 7.